Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report.
Grisariu S, Avni B, Batchelor TT, van den Bent MJ, Bokstein F, Schiff D, Kuittinen O, Chamberlain MC, Roth P, Nemets A, Shalom E, Ben-Yehuda D, Siegal T; International Primary CNS Lymphoma Collaborative Group. Grisariu S, et al. Among authors: kuittinen o. Blood. 2010 Jun 17;115(24):5005-11. doi: 10.1182/blood-2009-12-258210. Epub 2010 Apr 5. Blood. 2010. PMID: 20368468 Free PMC article.
Previous radiotherapy improves treatment responses and causes a trend toward longer time to progression among patients with immune checkpoint inhibitor-related adverse events.
Jokimäki A, Hietala H, Lemma J, Karhapää H, Rintala A, Kaikkonen JP, Sunela K, Boman E, Jukkola A, Tiainen S, Seppälä J, Rönkä A, Hakkarainen H, Kärnä A, Iivanainen S, Koivunen J, Auvinen P, Hernberg M, Kuusisto M, Selander T, Kuittinen O. Jokimäki A, et al. Among authors: kuittinen o. Cancer Immunol Immunother. 2023 Oct;72(10):3337-3347. doi: 10.1007/s00262-023-03494-4. Epub 2023 Jul 24. Cancer Immunol Immunother. 2023. PMID: 37486396 Free PMC article.
Real-world Data: MCL2 Protocol Demonstrates Excellent Treatment Results Among Patients With Mantle Cell Lymphoma Not Fulfilling the Original Trial Inclusion Criteria.
Harmanen M, Klaavuniemi T, Sorigue M, Khan M, Prusila R, Kari E, Alanne E, Rajamäki A, Sunela K, Jukkola A, Jantunen E, Sancho JM, Ketola S, Kuitunen H, Selander T, Rönkä A, Kuittinen O. Harmanen M, et al. Among authors: kuittinen o. Hemasphere. 2023 Sep 7;7(10):e954. doi: 10.1097/HS9.0000000000000954. eCollection 2023 Oct. Hemasphere. 2023. PMID: 37693119 Free PMC article. No abstract available.
Drug-induced pneumonitis risk in diffuse large B-cell/follicular lymphoma patients treated with R-CHOP-like regimen is associated with the use of granulocyte colony-stimulating growth factors.
Kaprio E, Prusila R, Tokola S, Kuusisto MEL, Jantunen E, Kuitunen H, Turpeenniemi-Hujanen T, Kuittinen O. Kaprio E, et al. Among authors: kuittinen o. Cancer Med. 2024 Jan 1;13(1):e6898. doi: 10.1002/cam4.6898. Online ahead of print. Cancer Med. 2024. PMID: 38164067 Free PMC article.
Loss of CD34+ Cells and Effect of the Number of Viable Cryopreserved CD34+ Cells in the Infused Blood Grafts on Hematologic Recovery, Progression-Free Survival and Overall Survival in NHL Patients After Autologous Stem Cell Transplantation.
Partanen A, Turunen A, Valtola J, Pyörälä M, Kuittinen O, Kuitunen H, Vasala K, Penttilä K, Kuittinen T, Mäntymaa P, Pelkonen J, Jantunen E, Varmavuo V. Partanen A, et al. Among authors: kuittinen o. Clin Lymphoma Myeloma Leuk. 2023 Nov;23(11):e428-e435. doi: 10.1016/j.clml.2023.08.009. Epub 2023 Aug 18. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37684185 Free article.
A practical prognostic peripheral blood-based risk model for the evaluation of the likelihood of a response and survival of metastatic cancer patients treated with immune checkpoint inhibitors.
Tiainen S, Nurmela V, Selander T, Turunen P, Pasonen-Seppänen S, Kettunen T, Kuittinen O, Auvinen P, Rönkä A. Tiainen S, et al. Among authors: kuittinen o. BMC Cancer. 2023 Dec 4;23(1):1186. doi: 10.1186/s12885-023-11699-0. BMC Cancer. 2023. PMID: 38049762 Free PMC article.
100 results